Vion's bacterial vectors

A simple observation often can lead to unexpected opportunities. Such was the case for Vion Pharmaceuticals Inc. researchers, who presented preclinical results last week on a new cancer therapy involving Salmonella bacteria at the American Association for Cancer Research meeting in San Diego.

VION scientists made a

Read the full 466 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers